Ovid Therapeutics Inc（OVID）の株式分析OVIDOvid Therapeutics Inc

Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ovid Therapeutics Inc is a good buy right now due to its current price of $2.80, which is significantly below the analyst price target of $7, indicating a potential upside of 150%. Additionally, the company has a strong cash position of $165.6 million, which supports ongoing R&D efforts, and a gross margin of 100% in recent quarters, showcasing its ability to maintain profitability on sales. However, a key risk is the negative net income reported, which was -$15 million in Q2 2026, indicating ongoing losses that investors should monitor closely.

4 analysts cover OVID: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.17.